The initiation of coverage by Leerink Partners with an Outperform rating and a specific price target of $32 suggests a positive outlook on LENZ Therapeutics' stock. This analyst endorsement can lead to increased investor interest and potentially drive the stock price up in the short term, especially if the market reacts positively to the analyst's projections.